A recent population-based study has shed light on a concerning trend: over half of older adults diagnosed with metastatic non-small cell lung cancer (NSCLC) are not receiving systemic treatments. This finding is particularly significant given the substantial advancements made in targeted therapies and immunotherapy approaches in recent years. The study suggests that even among patients who might be considered good candidates for treatment – those who are younger, have fewer co-existing health conditions (comorbidities), and survive for at least 90 days post-diagnosis – a substantial portion are still not undergoing treatment. The exact reasons for this treatment gap remain unclear, and it is difficult to ascertain how many individuals were too unwell to receive therapy. This highlights a potential disparity in care for this vulnerable patient population.
Metastatic non-small cell lung cancer (NSCLC) refers to lung cancer that has spread from its original location in the lung to other parts of the body. The NSCLC type is the most common form of lung cancer, accounting for about 80-85% of all lung cancer diagnoses. When NSCLC becomes metastatic, it means cancer cells have detached from the primary tumor and traveled through the bloodstream or lymphatic system to form new tumors in distant organs, such as the brain, bones, liver, or adrenal glands. This stage of cancer is generally more challenging to treat and often has a poorer prognosis.
Historically, treatment options for advanced lung cancer were limited, primarily relying on chemotherapy. However, the landscape of lung cancer treatment has been revolutionized by targeted therapies and immunotherapies. Targeted therapies are drugs designed to specifically attack cancer cells with certain genetic mutations or proteins that drive their growth and survival. For example, mutations like EGFR (epidermal growth factor receptor) and ALK (anaplastic lymphoma kinase) rearrangements are common in NSCLC and have specific targeted drugs (like osimertinib for EGFR, and crizotinib or alectinib for ALK) that can be highly effective. Immunotherapy, on the other hand, works by harnessing the patient’s own immune system to recognize and fight cancer cells. Drugs like pembrolizumab (Keytruda) are checkpoint inhibitors that block proteins that cancer cells use to hide from the immune system, allowing T-cells to attack them. These newer treatments have significantly improved survival rates and quality of life for many patients with NSCLC, especially those with specific molecular markers.
Despite these breakthroughs, the study’s findings indicate that a considerable number of older adults with metastatic NSCLC are not benefiting from these advanced treatment modalities. The lack of treatment could be due to a multitude of factors, including patient preference, physician recommendation, access to care, insurance coverage, and the presence of other severe health issues that contraindicate treatment. The study’s observation that even patients with seemingly fewer barriers to treatment are being left untreated suggests a systemic issue that requires further investigation. It’s possible that factors such as frailty assessments, understanding of potential benefits versus risks, and effective communication between healthcare providers and patients play a crucial role.
Older adults, in particular, can face unique challenges when dealing with cancer. They may have multiple chronic conditions, which can complicate treatment decisions and increase the risk of side effects. However, age alone should not be an automatic barrier to receiving potentially life-extending treatments. A comprehensive assessment of an individual’s overall health, functional status, and personal goals is essential in determining the most appropriate course of action. The concept of ‘fitness’ for treatment in older adults is complex and should not be solely based on chronological age.
The study’s implication that younger age, fewer comorbidities, and survival past 90 days are indicators of potential treatment candidacy, yet still result in untreated individuals, points towards a critical need for improved screening, assessment, and access to these advanced therapies for the elderly population. This could involve dedicated geriatric oncology services, multidisciplinary tumor boards that include specialists in geriatrics, and patient navigation programs to help patients and their families understand their options and overcome logistical hurdles. Furthermore, ongoing research is crucial to better understand the specific reasons for undertreatment and to develop strategies to ensure equitable access to care for all eligible patients, regardless of age or other health factors.
It is imperative that healthcare systems and providers address this disparity to ensure that all patients with metastatic NSCLC have the opportunity to benefit from the most effective and appropriate treatment options available, thereby improving their prognosis and quality of life. The findings of this study underscore the importance of a personalized and evidence-based approach to cancer care, especially for older adults.
Source: mdsc.pe
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
lung cancer treatment options by stage success rate 4 cost without insurance guidelines treatments and cures drugs advances prognosis survival algorithm prevention after lobectomy surgery australia palliation evidencebased articles based on breakthrough best hospitals brain metastasis bangla 3 bronchoscopy chemotherapy centers in india with canada malaysia tata memorial hospital uk drug names duration diet developments dogs doctor dexamethasone diagram discovery effectiveness early stages expenses elderly egfr evolution esmo mutation europe for cats 85 year old 80 found 90 non small cell germany nccn google scholar genetic markers nhs hindi how long holistic history home hong kong hair loss hyponatremia cuba mexico immunotherapy saudi arabia improvements marathi tamil japan journal management impact factor jaipur johns hopkins johnson do doctors treat much keytruda kannada kolkata korea ka kaise hota hai kerala kanpur life expectancy length lahore last latest laser no first line palliative care spread to liver medicine mayo clinic medications malayalam methods modalities market name near me news not working nz nice nih what types of are available oral medication outcomes age osimertinib overview plan pill protocol philippines price ppt process pathway procedure reddit radiation research regimens radiotherapy review recovery time russia vs chemo 2 1 side effects rates statistics singapore timeline tablets targeted therapy trials telugu tki targets usa uptodate updates us cure new private vaccines video via nebulizer vaccine vietnam cmc vellore braf v600e vijayawada is severe copd emphysema when an option youtube years 20 progress yamunanagar usually treated curable zealand there any the current older adult health disparities screening healthcare assess 30 hub cockburn issues ati adults promotion assessment persons peoples auckland literacy mental awareness day 2025 burwood behavioral initiative network specialist unit oregon bone conditions center collective christchurch contact number canterbury people senior check dunedin drink lgbt dubbo daw park doncaster devonport ecu education elk grove village edapt quizlet eastern email exeter resource expo address aid fremantle facts flinders person course fmc referral form fraser national fitness griffith greenlane guernsey gold coast gosport gosford hobart hawkes bay hornsby team hereford inequalities sub saharan africa inpatient isle man jobs jersey joondalup nurse service kidman kirwan langley legislation launceston lismore logan liverpool mcknights services vancouver osborne problems occupational world organization opmh oxford definition phone princess margaret program perth palmerston north peel qld mood questionnaire needs risks rockingham resources richmond rch sexual strategy sechelt surrey support topics medical term training sheffield bromsgrove photos reviews wollongong kogarah nsw st george newcastle vch victoria wellington wanneroo ward white rock worcestershire week worcester walsall xpress yahoo foods should avoid metastatic nsclc icd 10 meaning adenocarcinoma abbreviation where does alk positive adrenal glands blood clots stroke biopsy bilateral mri mets cough causes coughing up ct scan cxr chest x ray dog diagnosis dx code death symptoms egfrm end epidemiology full from colon forum breast sarcoma kidney prostate melanoma financial assistance final gross gland live hereditary histology can you survive terminal incidence keynote aggressive left lymph nodes median mortality nonsquamous smoker nodules overall certificate origin standard osteosarcoma prevalence pembrolizumab patients pathophysiology pleural fluid pain progression radiology ribbon color right risk factors radiopaedia remission scc squamous sites intrathoracic node mediastinum unspecified unknown primary effusion it 5